trending Market Intelligence /marketintelligence/en/news-insights/trending/5h1F2phQjZRnhwSJFznW2w2 content esgSubNav
In This List

Alliance Pharma completes acquisition of TyraTech's head lice treatment

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Alliance Pharma completes acquisition of TyraTech's head lice treatment

Alliance Pharma plc completed its acquisition of the worldwide rights to TyraTech, Inc.'s Vamousse.

TyraTech's shareholders approved the deal on Dec. 27.

Vamousse assets comprise consumer healthcare products for preventing and treating human head lice.